Cytosolic/microsomal redox pathway: A reductive retention mechanism of a PET-oncology tracer, Cu-pyruvaldehyde-bis(N4-methylthiosemicarbazone) (Cu- PTSM)

Annals of Nuclear Medicine

Volumn 13, Issue 5, 1999, Pages 287-292

  Shibuya, Keiko ^a   Fujibayashi, Yasuhisa ^b   Yoshimi, Eiji ^b   Sasai, Keisuke ^b   Hiraoka, Masahiro ^b   Welch, Michel J ^b  

^a KYOTO UNIVERSITY   (Japan)

^b NONE

Author keywords

Complex I; Cu PTSM; Electron transport; NADH; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; COPPER 62; METHYLGLYOXAL; MITOCHONDRIAL ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; THIOSEMICARBAZONE DERIVATIVE;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOSOL; DRUG ACTIVATION; DRUG METABOLISM; DRUG RETENTION; ELECTRON SPIN RESONANCE; ELECTRON TRANSPORT; ENZYME ACTIVITY; GLIOBLASTOMA; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MICROSOME; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0032704840     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03164865     Document Type: Article

References (30)

1. Fujibayashi Y, Matsumoto K, Yonekura Y, Konishi J, Yokoyama A. A new zinc-62/copper-62 generator as a copper-62 source for PET radiopharmaceuticals. J Nucl Med 30: 1838-1842, 1989.
2. 62Cu-PTSM) in the murine brain; a novel radiopharmaceutical for brain positron emission tomography (PET) imaging. Biol Pharm Bull 16: 146-149, 1993.
3. 62Cu-PTSM. Nucl Med Biol 19: 39-44, 1992.
4. Okazawa H, Yonekura Y, Fujibayashi Y, Nishizawa S, Magata Y, Ishizu K, et al. Clinical application and quantitative evaluation of generator-produced copper-62-PTSM as a brain perfusion tracer for PET. J Nucl Med 35: 1910-1915, 1994.
5. 14C-iodoantipyrine. Nucl Med Biol 21: 613-617, 1994.
6. Taniuchi H, Fujibayashi Y, Yonekura Y, Konishi J, Yokoyama A. Hyperfixation of copper-62-PTSM in rat brain after transient global ischemia. J Nucl Med 38: 1130-1134, 1997.
7. Mathias CJ, Welch MJ, Perry DJ, McGuire AH, Zhu X, Connett JM, et al. Investigation of copper-PTSM as a PET tracer for tumor blood flow. Int J Rad Appl Instrum B 18: 807-811, 1991.
8. Mathias CJ, Green MA, Morrison WB, Knapp DW. Evaluation of Cu-PTSM as a tracer of tumor perfusion: comparison with labeled microspheres in spontaneous canine neoplasms. Evaluation of Cu-PTSM as a tracer of tumor perfusion: comparison with labeled microspheres in spontaneous canine neoplasms. Nucl Med Biol 21: 83-87, 1994.
9. 4-methylthiosemicarbazone) (Cu-PTSM) by brain and tumor: a novel radiopharmaceutical for positron emission tomography imaging. Ann Nucl Med 9: 1-5, 1995.
10. Shibamoto Y, Takahashi M, Ono K, Komuro C, Abe M. Recovery from potentially lethal damage after X-irradiation in three experimental tumors in mice. Jpn J Cancer Res 76: 278-283, 1985.
11. Menkel DT, Petering DH. Initial reaction of 3-ethoxy-2-oxobytyraldehyde bis(thiosemicarbazonato)coper(II) with Ehrlich ascites tumor cells. Cancer Res 38: 117-123, 1978.
12. Voss DO, Camplleo AP, Bacila M. The respiratory chain and the oxidative phosphorylation of rat brain mitochondria. Biochem Biophys Res Commun 4: 48-51, 1961.
13. Pennington RJ. Biochemistry of dystrophic muscle; mitochondrial succinate-tetrazolium reductase and adenosine triphosphatase. Biochem J 80: 649-654, 1961.
14. 5 and NADPH-cytochrome c reductase from rat liver microsomes. J Biochem 67: 249-257, 1970.
15. Komherg A. Lactate dehydrogenase of muscle. In: Medhods in Enzymology, vol. 1, pp. 441-443, 1955.
16. Warren LE, Horner SM, Hatfield WE. Chemistry of alpha-diketone-bis(thiosemicarbazone)copper(II) complexes. J Amer Chem Soc 94: 6392-6396, 1972.
17. Dietzen DJ, Davis EJ. Oxidation of pyruvate, malate, citrate, and cytosolic reducing equivalents by AS-30D hepatoma mitochondria. Arch Biochem Biophys 305: 91-102, 1993.
18. Pedersen HL. Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Rev 22: 190-274, 1978.
19. Eigenbrodt E, Fister P, Reinacher M. New perspectives on carbohydrate metabolism in tumor cells. In: Regulation of Carbohydrate Metabolism, vol. 2. CRC Press: Oxford, pp. 141-179, 1986.
20. Chance H, Williamson JR, Jamieson D, Schoener H. Properties and kinetics of reduced pyridine nucleotide fluorescence of the isolated and in vivo rat heart. Biochem Zeit 341: 357-377, 1965.
21. Kogure K, Busto R, Schwartzman RJ, Scheinberg P. The dissociation of cerebral blood flow, metabolism and function in the early stages of developing cerebral infarction. Annals Neurol 8: 278-290, 1979.
22. Waki A, Fujibayashi Y, Yonekura Y, Sadato N, Ishii Y, Yokoyama A. Reassessment of FDG uptake in tumor cells: high FDG uptake as a reflection of oxygen-independent glycolysis dominant energy production. Nucl Med Biol 24: 665-670, 1997.
23. +: NADH ratio in normal and transformed fibroblasts. J Biol Chem 249: 4138-4143, 1974.
24. Darville MI, Antoine IV, Mertens-Strijthagen JR, Dupriez VJ, Roussenu GG. An E2F-dependent late-serum-response promoter in a gene that controls glycolysis. Oncogene 11: 1509-1517, 1995.
25. Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R, Lewis AD. Reductase enzyme expression across the National Cancer Institute Tumor Cell Line Panel: correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 88: 259-269, 1996.
26. Walton MI, Workman P. Enzymology of the reductive bioactivation of SR4233. Biochem Phamacol 39: 1735-1742, 1990.
27. Workman P, Stratford IJ. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metast Rev 12: 73-82, 1993.
28. Petering DH. Carcinostatic copper complexes. In: Metal Ions in Biological Systems, vol. 11. Marcel Dekker, Inc.: New York, pp. 198-229, 1980.
29. Kilkuskie RE, Macdonald TL, Hecht SM. Bleomycin may be activated for DNA cleavage by NADPH-cytochrome P-450 reductase. Biochem 23: 6165-6171, 1984.
30. Biaglow JE, Cerniglia G, Tuttle S, Bakanauskas V, Stevens C, McKenna G. Effect of oncogene transformation of rat embryo cells on cellular oxygen consumption and glycolysis. Biochem Biophys Res Commun 235: 739-742, 1997.